[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584874":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":49,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Guangzhou JOYO Pharma Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"JYP0015 in RAS-Mutant Solid Tumors","EXPERIMENTAL","This arm includes participants with histologically or pathologically confirmed advanced solid tumors harboring RAS mutations, identified via molecular testing. RAS mutations are defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, 61, 117, or 146 (e.g., G12, G13, Q61, K117, or A146). Participants will receive JYP0015 as an oral tablet.",[13],"Drug: JYP0015",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","JYP0015","JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol in the dose-escalation and indication-expansion phases.",[9],null,[22,28],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Ling Shen, M.D.","CONTACT","01088121122","+86","linshenpku@163.com",{"name":29,"role":24,"phone":20,"phoneExt":20,"email":20},"Xiao",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":47,"role":24,"phone":48,"phoneExt":26,"email":27},"Shen Lin, M.D.","010-88196861",{"type":50,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100584874","phase-2-study-of-jyp0015-in-patients-with-advanced-solid-tumors-harboring-specific-mutations-in-ras-100584874",false,"NCT06895031","Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","A Multi-center, Open-label, Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation","STAR","Inclusion Criteria:\n\n1. Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.\n2. Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment\n3. Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1\n4. Adequate organ function\n\nExclusion Criteria:\n\n1. Presence of central nervous system (CNS) metastases; however, subjects with previously treated brain metastases may be enrolled if clinically stable.\n2. Gastrointestinal (GI) disorders that may interfere with drug administration\u002Fabsorption, including but not limited to: Dysphagia or inability to swallow tablets， Malabsorption syndrome，Refractory nausea, vomiting, or diarrhea，Chronic GI diseases (e.g., Crohn's disease, ulcerative colitis)\n3. Congestive heart failure with New York Heart Association (NYHA) functional class ≥II or left ventricular ejection fraction (LVEF) \\\u003C50%.\n4. Any other condition deemed by the investigator to potentially compromise study outcomes or lead to premature termination, including but not limited to: Alcohol or substance abuse，Concurrent severe medical conditions (e.g., psychiatric disorders requiring active treatment)， Familial or social circumstances that may affect patient safety, compliance, or study data collection.","ALL","18 Years","75 Years",{"count":63,"type":64},210,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.",[70,71,72,73],"Solid Tumor","Pancreatic Ductal Adenocarcinoma (PDAC)","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)",[75,76,77],"PDAC","NSCLC","CRC","2026-03-04",{"date":80,"type":81},"2026-03-06","ACTUAL",{"date":83,"type":81},"2025-03-31",{"date":85,"type":64},"2026-12-31",{"name":5,"class":6},1]